The 10-second takeaway
For the quarter ended March 31 (Q1), Medidata Solutions beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share expanded.
Gross margins expanded, operating margins expanded, and net margins contracted.
Medidata Solutions reported revenue of $50.4 million. The eight analysts polled by S&P Capital IQ foresaw sales of $49.1 million on the same basis. GAAP reported sales were 24% higher than the prior-year quarter's $40.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.15. The seven earnings estimates compiled by S&P Capital IQ predicted $0.13 per share. GAAP EPS of $0.15 for Q1 were 15% higher than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 71.0%, 310 basis points better than the prior-year quarter. Operating margin was 12.1%, 360 basis points better than the prior-year quarter. Net margin was 7.5%, 30 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $52.8 million. On the bottom line, the average EPS estimate is $0.20.
Next year's average estimate for revenue is $211.5 million. The average EPS estimate is $0.78.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 44 members rating the stock outperform and three members rating it underperform. Among 11 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), all 11 give Medidata Solutions a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medidata Solutions is outperform, with an average price target of $26.86.
The health-care investing landscape is littered with also-rans and a few major winners. Is Medidata Solutions performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Medidata Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.